Abstract:Background: The understanding of alterations within the immune system following doxorubicin (DOX) chemotherapy, and subsequent restoration, in childhood cancer survivors remains limited. This investigation endeavors to elucidate the immediate and delayed changes in thymic immune cell populations and their phenotypes in response to clinically relevant low doses of DOX in a juvenile mouse model. Methods: Male mice underwent a regimen of repeated low-dose DOX intraperitoneal injections at 4 mg/kg/week for three consecutive weeks. One week after the last dose of DOX, a subset of mice was euthanized to assess the immediate effects of DOX administration. A second subset of mice was euthanized five weeks after the last DOX dose to evaluate the delayed effects. Thymic samples were collected for multiparameter flow cytometry analysis to evaluate alterations in immune cell composition and phenotype. Additionally, quantitative real-time polymerase chain reaction (qRT-PCR) was employed to measure gene expression of- cytokines and senescence markers. Results: One week following DOX administration, DOX treatment resulted in significant decline in thymus weight, with notable alterations in immune cell subpopulations. Reduced frequencies of mature CD3+CD4+ and CD3+CD8+ T cells were observed, along with changes in proliferation and exhaustion markers. Gene expression analysis revealed upregulation of Foxn, Pax1, Ifnγ, and Il7 alongside decreased Il6 and Il17 expression. Furthermore, Cdkn1a (p21Cip1) expression was elevated, suggesting immunosenescence. Five weeks following DOX administration, delayed effects of DOX treatment manifested in rebound increase in thymus weight and altered frequencies of CD4+ and CD8+ T cell subsets, with distinct patterns of proliferation and exhaustion observed. Notably, central memory CD4+ T cells exhibited significant decrease in frequency, while naive and effector memory CD4+ T cells showed reduced proliferation (Ki67+) and PD1 expression. Similar trends were observed in CD8+ T cell subsets, indicating selective effects of DOX on T cell differentiation and function. Although expression of thymus-related genes was normalized, p21Cip1 gene expression remained elevated. Conclusion: DOX treatment elicits a multifaceted influence on immune cell subsets and thymic weight. Immediate effects included thymic atrophy and reductions in mature T cell populations, while delayed effects showed rebound thymic hyperplasia and selective changes in CD4+ and CD8+ T cell subsets. Notably, both central memory and effector memory T cells exhibited reduced proliferation and exhaustion, suggesting unique impacts of DOX on immune cell function. The enduring elevation in p21Cip1 gene expression 5 weeks after DOX treatment suggests an immunosenescent phenotype. These observations collectively illuminate the formidable task of preserving immune competence and overall well-being in childhood cancer survivors subjected to DOX therapy.

Doxycycline Up-Regulates the Expression of IL-6 and GM-CSF Via MAPK/ERK and NF-κB Pathways in Mouse Thymic Epithelial Cells.

Doxycycline Enhances the Ras‐MAPK Signaling and Proliferation of Mouse Thymic Epithelial Cells

Analysis of the Protein Expression Profile of Thymic Epithelial Cells Treated with or Without Doxycycline Action

Effects of Antioxidant and Nitric Oxide on Chemokine Production in Tnf-Alpha-Stimulated Human Dermal Microvascular Endothelial Cells

Doxycycline Protect MTEC1 Cells Against the Cell Apoptosis Induced by Mitomycin and Preliminary Analysis for the Proteomic of MTEC1 Exposed to Doxycycline

Doxycycline Exerts Multiple Anti-Allergic Effects in Vitro and in Vivo Though Modulating PI3K/Akt Pathway (HYP6P.269)

Egf Protects Cells Against Dox-Induced Growth Arrest Through Activating Cyclin D1 Expression

Regulation of murine lymphokine production in vivo. III. The lymphoid tissue microenvironment exerts regulatory influences over T helper cell function

Doxycycline Reverses Epithelial-to-mesenchymal Transition and Suppresses the Proliferation and Metastasis of Lung Cancer Cells

Minocycline up-regulates the expression of brain-derived neurotrophic factor and nerve growth factor in experimental autoimmune encephalomyelitis

Dexamethasone Enhances Programmed Cell Death 1 (PD-1) Expression During T Cell Activation: an Insight into the Optimum Application of Glucocorticoids in Anti-Cancer Therapy

Doxycycline Exerts Multiple Anti-Allergy Effects to Attenuate Murine Allergic Conjunctivitis and Systemic Anaphylaxis

[Inhibitory Effect of Dexamethasone on Myeloid Differentiation Factor 88 and Tumor Necrosis Factor-Alpha Expressions in Mouse Peritoneal Macrophages].

Up-Regulation Of Th17 Cells May Underlie Inhibition Of Treg Development Caused By Immunization With Activated Syngeneic T Cells

The effect of long-term doxycycline treatment in a mouse model of cigarette smoke-induced emphysema and pulmonary hypertension

Doxycycline for transgene control disrupts gut microbiome diversity without compromising acute neuroinflammatory response

The Cryo-Thermal Therapy-Induced Il-6-Rich Acute Pro-Inflammatory Response Promoted Dcs Phenotypic Maturation As The Prerequisite To Cd4(+) T Cell Differentiation

Tetracyclines Enhance Anti-tumor T-Cell Responses Induced by a Bispecific T-Cell Engager

Up-regulation of IL-10 expression in dendritic cells is involved in Trichosanthin-induced immunosuppression

Doxycycline Suppresses Cerebral Matrix Metalloproteinase-9 and Angiogenesis Induced by Focal Hyperstimulation of Vascular Endothelial Growth Factor in a Mouse Model

Divergent Immediate and Delayed Effects of Juvenile Exposure to Doxorubicin on the Thymus in C57BL/6 Mice